Taubenschmid-Stowers and colleagues used COs engineered to carry mutations of the tumor suppressor genes TP53, NF1, and PTEN, together with GFP labeling, which allowed monitoring of tumor growth over time [30]. Here, TP53 is linked to neoplasm.